Nikhil C. Munshi

7 ta ish

Harvard University

1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

   Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25

   Maqola20217 iqtibos

   ABIABI:AkademIndex/2026.other.296878

2. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

   Noopur Raje, Jesús G. Berdeja, Yi Lin +20

   MaqolaOAOchiq kirish20195 iqtibos

   ABIABI:AkademIndex/2026.other.082848

3. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

   Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani +33

   Maqola20214 iqtibos

   ABIABI:AkademIndex/2026.other.475845

4. Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by <i>Nanoparticle Albumin-Bound</i> –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma

   Diana Cirstea, Teru Hideshima, Scott J. Rodig +15

   MaqolaOAOchiq kirish20102 iqtibos

   ABIABI:AkademIndex/2026.other.003075

5. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

   Mark Bustoros, Romanos Sklavenitis‐Pistofidis, Jihye Park +33

   Maqola20202 iqtibos

   ABIABI:AkademIndex/2026.other.312695

6. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

   Hervé Avet‐Loiseau, Faith E. Davies, Mehmet Samur +43

   Maqola20252 iqtibos

   ABIABI:AkademIndex/2026.other.480252

7. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo

   Eugenio Morelli, Emanuela Leone, Maria Eugenia Gallo Cantafio +13

   Maqola20152 iqtibos

   ABIABI:AkademIndex/2026.other.816460